Research Summaries

Adding Immune-Based Drug to Standard Treatment Controls the Growth of Multiple Myeloma for Longer

ASCO Annual Meeting
May 13, 2015

As part of an ongoing study, researchers found that a new immune-based treatment controlled the growth of multiple myeloma for longer than standard treatment. This new treatment, elotuzumab, works in two different ways to treat myeloma. It is able to directly target multiple myeloma cells and boost a part of the immune system that helps control the growth of cancer cells.

Adding Docetaxel to Standard Prostate Cancer Treatment Lengthens Lives

ASCO Annual Meeting
May 13, 2015

A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.

Adding to Standard Treatment Increases the Number of Children Cured of Wilms Tumor

ASCO Annual Meeting
May 13, 2015

Two phase III Children’s Oncology Group studies found that using additional drugs with standard therapy lowered the chance that Wilms tumor with a specific genetic change returned after treatment. Wilms tumor is a rare type of cancer that begins in a child’s kidney. When it comes back after treatment, it is called a relapse or recurrence.

Nearly a Third of Patients with Cancer Experience Anxiety or Other Mental Health Challenges

JCO Research Round Up
October 16, 2014 

One in three patients with cancer experiences anxiety or other mental health challenges, according to a study published in the Journal of Clinical Oncology. This is the largest and most comprehensive study to date assessing the mental and emotional health of patients with cancer using a standardized, diagnostic face-to-face interview.

Pages

Subscribe to RSS - Research Summaries